Dr. Robert S. Rosenson of Mount Sinai Health System discusses with Dr. Ron Waksman the results of study into the first 12-week treatment period with evinacumab of patients with severe hypertriglyceridemia. The study, presented as a late-breaking trial at ACC.21 Virtual, showed triglyceride patients of around 80%  in patients with minimal mutations in lipoprotein lipase, while those with more mutations had essentially no benefit.